Hu Zhang1, You-Qing Zhu1, Ya-Qiong Wu1, Ping Zhang1, Jian Qi1. 1. Hu Zhang, You-Qing Zhu, Jian Qi, Department of Gastroenterology and Clinical Center of Intestinal and Colorectal Diseases of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China.
Abstract
AIM: To investigate the feasibility of detecting aberrantly hypermethylated Wnt-antagonist gene promoters (SFRP2 and WIF-1) in fecal DNA as non-invasive biomarkers for early colorectal cancer (CRC). METHODS: The methylation-specific polymerase chain reaction assay was performed to blindly analyze the methylation status of SFRP2 and WIF-1 gene promoters in fecal samples from 48 subjects with CRC, 35 with adenomas, 32 with hyperplastic polyps and 30 endoscopically normal subjects. Additionally, we compared the diagnostic efficiency of measuring the hypermethylated SFRP2 and WIF-1 genes in the feces to the fecal occult blood test (FOBT) for the early detection of CRC. RESULTS: Hypermethylated SFRP2 was detected in the feces of 56.3% (27/48) of CRC cases, 51.4% (18/35) of adenoma cases and 12.5% (4/32) of patients with hyperplastic polyps. The hypermethylation of WIF-1 was detected in 60.4% (29/48), 45.7% (16/35) and 18.7% (6/32) of fecal samples from CRC, adenoma and hyperplastic polyp patients, respectively. At least one hypermethylated gene was detected in 81.3% (39/48) of CRC and 65.7% (23/35) of adenoma samples. In contrast, only a hypermethylated WIF-1 gene was detected in one case of normal fecal samples. Moreover, no significant associations were observed between SFPR2 and WIF-1 hypermethylation and clinicopathological features. Additionally, 81.8% of CRC cases diagnosed as Dukes A stage or advanced adenomas had at least one hypermethylated gene detected, while the detection rate with the FOBT was only 31.8% (P < 0.001). CONCLUSION: Hypermethylated SFRP2 and WIF-1 genes in fecal DNA are novel and promising molecular biomarkers that have great diagnostic potential for early CRC.
AIM: To investigate the feasibility of detecting aberrantly hypermethylated Wnt-antagonist gene promoters (SFRP2 and WIF-1) in fecal DNA as non-invasive biomarkers for early colorectal cancer (CRC). METHODS: The methylation-specific polymerase chain reaction assay was performed to blindly analyze the methylation status of SFRP2 and WIF-1 gene promoters in fecal samples from 48 subjects with CRC, 35 with adenomas, 32 with hyperplastic polyps and 30 endoscopically normal subjects. Additionally, we compared the diagnostic efficiency of measuring the hypermethylated SFRP2 and WIF-1 genes in the feces to the fecal occult blood test (FOBT) for the early detection of CRC. RESULTS: Hypermethylated SFRP2 was detected in the feces of 56.3% (27/48) of CRC cases, 51.4% (18/35) of adenoma cases and 12.5% (4/32) of patients with hyperplastic polyps. The hypermethylation of WIF-1 was detected in 60.4% (29/48), 45.7% (16/35) and 18.7% (6/32) of fecal samples from CRC, adenoma and hyperplastic polyppatients, respectively. At least one hypermethylated gene was detected in 81.3% (39/48) of CRC and 65.7% (23/35) of adenoma samples. In contrast, only a hypermethylated WIF-1 gene was detected in one case of normal fecal samples. Moreover, no significant associations were observed between SFPR2 and WIF-1 hypermethylation and clinicopathological features. Additionally, 81.8% of CRC cases diagnosed as Dukes A stage or advanced adenomas had at least one hypermethylated gene detected, while the detection rate with the FOBT was only 31.8% (P < 0.001). CONCLUSION: Hypermethylated SFRP2 and WIF-1 genes in fecal DNA are novel and promising molecular biomarkers that have great diagnostic potential for early CRC.
Authors: Amit K Gupta; L Joseph Melton; Gloria M Petersen; Lawrence J Timmons; Santhi Swaroop Vege; William S Harmsen; Nancy N Diehl; Alan R Zinsmeister; David A Ahlquist Journal: Clin Gastroenterol Hepatol Date: 2005-02 Impact factor: 11.382
Authors: Wei-Dong Chen; Z James Han; Joel Skoletsky; Jeff Olson; Jerome Sah; Lois Myeroff; Petra Platzer; Shilong Lu; Dawn Dawson; Joseph Willis; Theresa P Pretlow; James Lutterbaugh; Lakshmi Kasturi; James K V Willson; J Sunil Rao; Anthony Shuber; Sanford D Markowitz Journal: J Natl Cancer Inst Date: 2005-08-03 Impact factor: 13.506
Authors: Hiromu Suzuki; D Neil Watkins; Kam-Wing Jair; Kornel E Schuebel; Sanford D Markowitz; Wei Dong Chen; Theresa P Pretlow; Bin Yang; Yoshimitsu Akiyama; Manon Van Engeland; Minoru Toyota; Takashi Tokino; Yuji Hinoda; Kohzoh Imai; James G Herman; Stephen B Baylin Journal: Nat Genet Date: 2004-03-14 Impact factor: 38.330
Authors: Barbara Kinga Barták; Alexandra Kalmár; Bálint Péterfia; Árpád V Patai; Orsolya Galamb; Gábor Valcz; Sándor Spisák; Barnabás Wichmann; Zsófia Brigitta Nagy; Kinga Tóth; Zsolt Tulassay; Péter Igaz; Béla Molnár Journal: Epigenetics Date: 2017-09-26 Impact factor: 4.528